A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Public ClinicalTrials.gov record NCT05878717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)
Study identification
- NCT ID
- NCT05878717
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 300 participants
Conditions and interventions
Interventions
- Belimumab Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2023
- Primary completion
- May 16, 2029
- Completion
- Jul 11, 2029
- Last update posted
- Jan 11, 2026
2023 – 2029
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Phoenix | Arizona | 85027 | Completed |
| GSK Investigational Site | Scottsdale | Arizona | 85258 | Recruiting |
| GSK Investigational Site | Scottsdale | Arizona | 85259 | Recruiting |
| GSK Investigational Site | Tucson | Arizona | 85724 | Recruiting |
| GSK Investigational Site | Los Angeles | California | 90095 | Recruiting |
| GSK Investigational Site | Los Angeles | California | 90301 | Recruiting |
| GSK Investigational Site | Upland | California | 91786 | Recruiting |
| GSK Investigational Site | Aurora | Colorado | 80033 | Recruiting |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20007 | Recruiting |
| GSK Investigational Site | Jacksonville | Florida | 32610 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33144 | Recruiting |
| GSK Investigational Site | Chicago | Illinois | 60611 | Recruiting |
| GSK Investigational Site | Baltimore | Maryland | 21224 | Recruiting |
| GSK Investigational Site | Ann Arbor | Michigan | 48109 | Recruiting |
| GSK Investigational Site | New Brunswick | New Jersey | 08901 | Recruiting |
| GSK Investigational Site | New York | New York | 10021 | Recruiting |
| GSK Investigational Site | New York | New York | 11201 | Recruiting |
| GSK Investigational Site | Potsdam | New York | 13676 | Recruiting |
| GSK Investigational Site | Cincinnati | Ohio | 45206 | Recruiting |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19104 | Recruiting |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | Recruiting |
| GSK Investigational Site | Denison | Texas | 75020 | Recruiting |
| GSK Investigational Site | El Paso | Texas | 79902 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05878717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05878717 live on ClinicalTrials.gov.